EFFICACY PLUS CARDIOPROTECTION IN

PRODUCT

Globally, 32.2% of all persons with Type 2 Diabetes are affected by CVD.1

Type 2 diabetes reduces life
expectancy by as much as 10 years1

The main cause of death is CVD1

EFFICACY PLUS CARDIOPROTECTION IN ONE PRODUCT

SYNJARDY® for patients with type 2 diabetes mellitus and high cardiovascular risk - reduce the risk of cardiovascular death or hospitalisation for heart failure2

Glycaemic control

Prevention of cardiovascular events

HBA1c REDUCTION EFFICACY

  • SYNJARDY® (empagliflozin + metformin combination in one tablet) offers statistically significant and clinical meaningful reductions in HbA1c3
  • Change in baseline HbA1c with SYNJARDY® ranged from -6.2 to -7.9 mmol/mol3
  • Pronounced reduction of up to 70% of patients achieve the HbA1c target of <7%3

Graph showing the change in HbA1c from baseline with twice daily SYNJARDY®
(empagliflozin + metformin)3

INDIRECT COMPARISON OF HBA1c IN PATIENTS WITH BASELINE >9%3

PERCENTAGE OF PATIENTS ACHIEVING AN HBA1c <7 AT WEEK 24

Graph showing the percentage of patients achieving an HbA1c of less than 7 with twice daily SYNJARDY at week 243

WEIGHTLOSS

SYNJARDY®, treatment = a pronounced positive change in weight with a twice daily dosage3

Graph showing the percentage of patients achieving an HbA1c of less than 7 with twice daily SYNJARDY at week 243

CARDIOPROTECTION

38% Reduction

RRR in CV death 3.7% vs 5.9%4

  • Empagliflozin treatment resulted in a 38% relative risk reduction on CV death4
  • The long-term use of empagliflozin is supported and evidence provided for a reduction in cardiovascular risk4

INDIVIDUALISED TREATMENT

With SYNJARDY® you have a choice of 6 different dosage combinations to give you more options for the treatment of your diabetic patients2

synjardy® contains empagliflozin and metformin in a single tablet2

Available Synjardy® doses

2X DAILY EMPAGLIFLOZIN/METFORMIN

5/500 mg

5/850 mg

5/1000 mg

12.5/500 mg

12.5/850 mg

12.5/1000 mg

References: 1. Einarson TR, Acs A et al. Prevalence of cardiovascular disease in type 2 diabetes: a systematic literature review of scientific evidence from across the world in 2007–2017. Cardiovasc Diabetol (2018) 17:83. [Online] 2016 [Cited March 2022]; Available from URL: https://cardiab.biomedcentral.com/track/pdf/10.1186/s12933-018-0728-6.pdf. 2. SYNJARDY package insert dated 20 October 2020. 3. Hadjadji S, Rosenstock J et al. Initial Combination of Empagliflozin and Metformin in Patients with Type 2 Diabetes. Diabetes Care 2016;39:1718–1728. 4. Zinman B. Wanner C et al. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. N Eng J Med 2015;373:2117-28 [Online] 2016 [Cited March 2022]; Available from URL: https://www.nejm.org/doi/pdf/10.1056/NEJMoa1504720?articleTools=true.

S4 SYNJARDY® 5/500 mg: Each film-coated tablet contains empagliflozin 5 mg and metformin HCl 500 mg. Reg. No. 49/21.2/0915. S4 SYNJARDY® 5/850 mg: Each film-coated tablet contains empagliflozin 5 mg and metformin HCl 850 mg. Reg. No. 49/21.2/0916. S4 SYNJARDY® 5/1000 mg: Each film-coated tablet contains empagliflozin 5 mg and metformin HCl 1 000 mg. Reg. No. 49/21.2/0917. S4 SYNJARDY® 12,5/500 mg: Each film-coated tablet contains empagliflozin 12,5 mg and metformin HCl 500 mg. Reg. No. 49/21.2/0918. S4 SYNJARDY® 12,5/850 mg: Each film-coated tablet contains empagliflozin 12,5 mg and metformin HCl 850 mg. Reg. No. 49/21.2/0919. S4 SYNJARDY® 12,5/1000 mg: Each film-coated tablet contains empagliflozin 12,5 mg and metformin HCl 1 000 mg. Reg. No. 49/21.2/0920. NAMIBIA. NS2 Synjardy 5/500mg. 16.21.2/0210; NS2 SYNJARDY® 5/850 mg. 16.21.2/0211; NS2 SYNJARDY® 5/1000 mg 16.21.2/0212; NS2 SYNJARDY® 12.5/500 mg 16.21.2/0213; NS2 SYNJARDY® 12.5/850 mg 16.21.2/0214; NS2 SYNJARDY® 12.5/1000 mg 16.21.2/0215. BOTSWANA: S2 SYNJARDY® 5/500 mg: Each film-coated tablet contains empagliflozin 5 mg and metformin HCl 500 mg. Reg. No. BOT2203842. S2 SYNJARDY® 5/850 mg: Each film-coated tablet contains empagliflozin 5 mg and metformin HCl 850 mg. Reg. No. BOT2203843. S2 SYNJARDY® 5/1000 mg: Each film-coated tablet contains empagliflozin 5 mg and metformin HCl 1 000 mg. Reg. No. BOT2203844. S2 SYNJARDY® 12,5/500 mg: Each film-coated tablet contains empagliflozin 12,5 mg and metformin HCl 500 mg. Reg. No. BOT2203845. S2 SYNJARDY® 12,5/850 mg: Each film-coated tablet contains empagliflozin 12,5 mg and metformin HCl 850 mg. Reg. No. BOT2203846. S2 SYNJARDY® 12,5/1000 mg: Each film-coated tablet contains empagliflozin 12,5 mg and metformin HCl 1 000 mg. Reg. No. BOT2203847.

Pharmacovigilance: Health Care physicians can report any adverse event (lack of efficacy, off label use, overdose with or without AE, medication error with or without AE, drug abuse/misuse, drug interaction, occupational exposure, pregnancy/lactation exposure and therapeutical response increase and/or unexpected benefit) occurring during or after administration of a marketed Boehringer Ingelheim product they become aware of either by written or verbal means by contacting Boehringer Ingelheim’s responsible Pharmacovigilance unit using the below contact details: South Africa PV local South Africa. Email: PV_local_South_Africa@boehringer-ingelheim.com. https://www.boehringer-ingelheim.com/data-privacy https://www.boehringer-ingelheim.com/terms-use.

For full prescribing information refer to the package insert approved by the Medicines Regulatory Authority Applicant details: Ingelheim Pharmaceuticals (Pty) Ltd, Suite 1, Building 4, 2nd Floor, Waterfall Corporate Campus, 74 Waterfall Drive, Midrand, 2066. Cpy Reg. No. 1966/008618/07. BI Ref. No. PC-ZA-101702. Expiry Date June 2024